The S190R mutation in RSV-A F protein impairs nirsevimab binding and neutralization capacity
Virus Evolution · 19.01.2026 · 12 (1)
DOI: 10.1093/ve/veag002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Virus Evolution, online erschienen am 08.01.2026. Verfasst von Sapir Cordela und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron 1 St, Haifa 3525422, Israel. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rapoport Faculty of Medicine SPARK, The US-Israel Binational Science Foundation, The Israel Science Foundation, Israel-Canada Collaboration.
Abstract (Originalsprache)
In 2023, the US Food and Drug Administration approved the use of nirsevimab for the prevention of respiratory syncytial virus (RSV) infections in healthy infants. This marks an important milestone for using passive immunotherapy for the prevention of viral infections. Previous studies that examined RSV-A sequences from breakthrough infection of nirsevimab-treated infants indicated that the nirsevimab binding site in the RSV-A F protein remained intact. To explore possible nirsevimab-resistant mutations that occur outside the antibody binding site, we have dissected the RSV-A mutations landscape at a single-genome resolution following exposure to nirsevimab. We identified a single amino acid substitution (S190R) at the antigenic site V of the RSV-A F protein that emerged in the vast majority of the isolated viruses. We further demonstrated that the S190R mutation reduces the binding and neutralization capacity of nirsevimab by altering antibody accessibility to site Ø epitopes. Additionally, by analysing the replication of S190R RSV-A in cell lines and in primary human organoids, we illustrated that the S190R mutation impairs the viral fitness of RSV-A. Thus, our study provides insight into possible viral mechanisms that can contribute to RSV-A escape from nirsevimab-based immunization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron 1 St, Haifa 3525422, Israel.
- Hadassah Organoid Center, Hadassah Hebrew University Medical Center, Jerusalem 9112102, Israel.
ORCID-Profile: Yotam Bar-On
Förderung
- Rapoport Faculty of Medicine SPARK
- The US-Israel Binational Science Foundation
- The Israel Science Foundation, Israel-Canada Collaboration
- The Israeli Ministry of Science and Technology MOST: France-Israel Joint Projects
Zitieren
APA
Cordela, S., Harari, J., Moirangthem, R., Khaleafi, R., Kladnitsky, O., Duran, D., Grunewald, M., & Bar-On, Y. (2026). The S190R mutation in RSV-A F protein impairs nirsevimab binding and neutralization capacity. Virus Evolution, 12(1). https://doi.org/10.1093/ve/veag002
Vancouver
Cordela S, Harari J, Moirangthem R, Khaleafi R, Kladnitsky O, Duran D, et al. The S190R mutation in RSV-A F protein impairs nirsevimab binding and neutralization capacity. Virus Evolution. 2026;12(1). doi:10.1093/ve/veag002
BibTeX
@article{Cordela2026,
author = {Cordela, Sapir and Harari, Jhonatan and Moirangthem, Romila and Khaleafi, Raghad and Kladnitsky, Orly and Duran, Deborah and Grunewald, Myriam and Bar-On, Yotam},
title = {The S190R mutation in RSV-A F protein impairs nirsevimab binding and neutralization capacity},
journal = {Virus Evolution},
year = {2026},
volume = {12},
number = {1},
doi = {10.1093/ve/veag002}
}
EUVIMED